

# Table of contents

|          |                                            |           |
|----------|--------------------------------------------|-----------|
| <b>1</b> | <b>Introduction.....</b>                   | <b>1</b>  |
| 1.1      | Mast cells.....                            | 1         |
| 1.2      | Endoplasmic reticulum.....                 | 2         |
| 1.3      | Unfolded protein response .....            | 3         |
| 1.3.1    | PERK .....                                 | 4         |
| 1.3.2    | ATF6.....                                  | 4         |
| 1.3.3    | IRE1 $\alpha$ .....                        | 4         |
| 1.4      | KIRA6.....                                 | 7         |
| 1.5      | Fc $\epsilon$ RI-dependent signaling.....  | 7         |
| 1.5.1    | Fc $\epsilon$ RI .....                     | 7         |
| 1.5.2    | Signaling components .....                 | 8         |
| 1.6      | KIT .....                                  | 17        |
| 1.7      | SRC-family kinases (SFK).....              | 17        |
| <b>2</b> | <b>Aim of work.....</b>                    | <b>20</b> |
| <b>3</b> | <b>Material .....</b>                      | <b>21</b> |
| 3.1      | Chemicals.....                             | 21        |
| 3.2      | Kit Systems.....                           | 22        |
| 3.3      | Solutions.....                             | 23        |
| 3.4      | Cell culture media .....                   | 27        |
| 3.4.1    | Cell culture medium.....                   | 27        |
| 3.4.2    | Starvation medium .....                    | 27        |
| 3.4.3    | Stimulation medium .....                   | 27        |
| 3.5      | Stimulators.....                           | 28        |
| 3.6      | Reverse Transcription.....                 | 28        |
| 3.7      | Primer .....                               | 29        |
| 3.8      | Primary antibodies for Western Blot .....  | 29        |
| 3.9      | Secondary antibodies for Western Blot..... | 30        |
| 3.10     | Antibodies for ELISA.....                  | 30        |
| 3.11     | Antibodies/Dyes for FACS.....              | 30        |

|          |                                                            |           |
|----------|------------------------------------------------------------|-----------|
| 3.12     | Antibody for stimulation with DNP-HSA .....                | 30        |
| 3.13     | Recombinant Protein for ELISA .....                        | 31        |
| <b>4</b> | <b>Methods .....</b>                                       | <b>32</b> |
| 4.1      | Cell culture .....                                         | 32        |
| 4.2      | Western blot .....                                         | 33        |
| 4.2.1    | Sample generation .....                                    | 33        |
| 4.2.2    | SDS-PAGE .....                                             | 33        |
| 4.2.3    | Western blot .....                                         | 33        |
| 4.2.4    | Immunodetection .....                                      | 34        |
| 4.3      | Immunoprecipitation .....                                  | 34        |
| 4.4      | Real-time quantitative PCR (RT-qPCR) .....                 | 35        |
| 4.4.1    | Sample generation .....                                    | 35        |
| 4.4.2    | Reverse Transcription .....                                | 35        |
| 4.4.3    | RT-qPCR .....                                              | 35        |
| 4.5      | $\beta$ -hexosaminidase assay .....                        | 36        |
| 4.6      | Enzyme-Linked-Immunabsorbent Assay (ELISA) .....           | 37        |
| 4.7      | LAMP1 assay .....                                          | 38        |
| 4.8      | Calcium mobilization .....                                 | 38        |
| 4.9      | Statistics .....                                           | 39        |
| 4.10     | Illustrations .....                                        | 39        |
| <b>5</b> | <b>Results .....</b>                                       | <b>40</b> |
| 5.1      | KIRA6 reduces <i>Il6</i> mRNA expression levels .....      | 40        |
| 5.2      | KIRA6 reduces mast cell effector functions .....           | 42        |
| 5.3      | KIRA6 inhibits fundamental signaling pathways .....        | 46        |
| 5.4      | KIRA6 reduces $Ca^{2+}$ -mobilization .....                | 49        |
| 5.5      | KIRA6 inhibits Fc $\epsilon$ RI proximal signaling .....   | 52        |
| 5.6      | KIRA6 inhibits SHIP1 phosphorylation .....                 | 55        |
| 5.7      | KIRA6 effects on KIT .....                                 | 56        |
| 5.8      | Comparison of WT and <i>Lyn</i> <sup>-/-</sup> BMMCs ..... | 59        |
| 5.9      | Stimulus intensity and duration affect KIRA6 effects ..... | 63        |

|           |                                                                      |            |
|-----------|----------------------------------------------------------------------|------------|
| 5.10      | KIRA6 reduces <i>Xbp1</i> splicing in response to Thapsigargin ..... | 67         |
| 5.11      | Thapsigargin initiates cytokine production .....                     | 69         |
| 5.12      | <i>Gusb</i> is regulated by Thapsigargin .....                       | 71         |
| <b>6</b>  | <b>Discussion .....</b>                                              | <b>73</b>  |
| <b>7</b>  | <b>Summary .....</b>                                                 | <b>87</b>  |
| <b>8</b>  | <b>References .....</b>                                              | <b>88</b>  |
| <b>9</b>  | <b>Supplement .....</b>                                              | <b>98</b>  |
| <b>10</b> | <b>Acknowledgements .....</b>                                        | <b>115</b> |